This study is a Phase II, single center, randomized, double-blind, placebo-controlled study in male and female subjects, aged ≥ 19 years with mild to moderate seborrheic dermatitis of the face. All subjects will receive BID topical applications of PAC-14028 cream or vehicle for up to 4 weeks.

Inclusion Criteria:

• Male or female patients aged between 19 and 65 years old
• Clinical diagnosis of seborrheic dermatitis in the facial area with Erythema severity ≥ 2 and Scaling severity ≥ 2
• IGE (Investigator's Global Evaluation) Score 2 or 3

Exclusion Criteria:

• Patients with psoriasis, atopic dermatitis, facial acne, rosacea or perioral dermatitis
• Patients who have been infected with bacteria, fungi, virus and animal infectious disease on the facial area
• Patients who were administered topical antifungal agents, steroids, retinoids, or calcineurin suppressants for the treatment of seborrheic dermatitis within the last 2 weeks
• Patients who were administered systemic antifungal agents, steroids, retinoids, or immunosuppressants for the treatment of seborrheic dermatitis within the last 4 weeks
• Patients who were administered local antibiotics for the treatment of seborrheic dermatitis within the last 4 weeks
• Pregnant women, breastfeeding women or women of childbearing potential or women who are planning a pregnancy during the study